News more>>
  07/13/2015    | BeiGene Doses First Patient in Phase Ib Study of BGB-283, A Novel Second Generation B-RAF inhibitor
  06/19/2015    | BeiGene Announces IND Clearance for BGB-3111, a Bruton tyrosine kinase inhibitor
  06/05/2015    | BeiGene Enrolls First Patient in Phase I Study of BGB-A317, A Humanized Anti-PD-1 Monoclonal Antibody
  05/27/2015    | Make the World’s Best Anti-cancer Drugs (Dream Chaser)
  05/13/2015    | BeiGene Secures 600 Million RMB ($97 Million US) Financing
  04/07/2015    | BeiGene Announces Presentations at AACR Annual Meeting 2015
  03/11/2015    | China's BeiGene Selects SAFC CHOZN® Platform for Commercial Drug Development
  02/25/2015    | BeiGene to Present at the Cowen and Company 35th Annual Health Care Conference
  02/10/2015    | BeiGene to Present at the BIO CEO Investor Conference
  01/30/2015    | Dr. Jason Yang spoke at 4th Annual Clinical Development and Trials Asia Congress & 5th Annual Pharma R&D Asia Congress
  01/08/2015    | BeiGene to Present at the 33rd Annual J.P. Morgan Healthcare Conference
  12/09/2014    | BeiGene Announces Presentation at The American Society of Hematology Annual Meeting 2014
  11/14/2014    | BeiGene Completes 450 Million RMB (75 Million USD) Financing
  11/11/2014    | Dr. Jason Yang, Senior Vice President of Clinical Development spoke at ChinaTrials 7 Summit
  10/10/2014    | BeiGene Wins BEEA Science and Technology Innovation Award
  09/26/2014    | Dr. Lusong Luo spoke at EFPIA public conference
  09/15/2014    | BeiGene Receives Clinical Milestone Payment for Development of BGB-290
  09/04/2014    | Alice Tian and Na Li Recieved "Beijing overseas high-caliber talents" Award
  09/03/2014    | Boehringer Ingelheim and BeiGene Announce Strategic Supply and Manufacturing Agreement in China
  08/27/2014    | BeiGene Expands Management Team with Two Strategic Senior Positions
  08/26/2014    | BeiGene Enrolls First Patient in Phase 1 Study of BGB-3111
  07/08/2014    | BeiGene Enrolls First Patient in Phase 1 Study of BGB-290
07/01/2014    | BeiGene Wins "The best investment value Top 10 company in Chinese pharmaceutical industry 2014"
  06/30/2014    | Dr. Lusong Luo is invited to present in the National gastric cancer conference in Beijing
Copyright BeiGene LTD    |   Careers   |    Contact Us